Assess Fibrin in Brains With AD/ADRD
NCT05336695
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer Disease
- Dementia of Alzheimer Type
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 55 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Massachusetts General Hospital
- Last updated on ClinicalTrials.gov
- October 30, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.